Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Insight Molecular Diagnostics Inc. (IMDX : NSDQ)
 
 • Company Description   
Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn.

Number of Employees: 49

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.85 Daily Weekly Monthly
20 Day Moving Average: 149,934 shares
Shares Outstanding: 28.60 (millions)
Market Capitalization: $81.51 (millions)
Beta: 0.95
52 Week High: $4.75
52 Week Low: $1.92
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -4.04% -8.30%
12 Week 2.52% -12.44%
Year To Date 19.75% 12.16%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
15 CUSHING
-
IRVINE,CA 92618
USA
ph: 949-409-7600
fax: 510-521-3389
ir@oncocyte.com http://www.oncocyte.com
 
 • General Corporate Information   
Officers
Joshua Riggs - President and Chief Executive Officer and Director
James Liu - Vice President Accounting; Controller; Treasurer a
Andrea James - Chief Financial Officer
Andrew Arno - Director
Andrew J. Last - Director

Peer Information
Insight Molecular Diagnostics Inc. (HLIS)
Insight Molecular Diagnostics Inc. (AZTA)
Insight Molecular Diagnostics Inc. (APYI)
Insight Molecular Diagnostics Inc. (RNVA)
Insight Molecular Diagnostics Inc. (HMSY)
Insight Molecular Diagnostics Inc. (LRSI)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MEDICAL INFO SYS
Sector: Medical
CUSIP: 68235C206
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 28.60
Most Recent Split Date: 7.00 (0.05:1)
Beta: 0.95
Market Capitalization: $81.51 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.82 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 7.98
Price/Cash Flow: -
Price / Sales: 21.21
EPS Growth
vs. Year Ago Period: 76.99%
vs. Previous Quarter: -154.17%
Sales Growth
vs. Year Ago Period: 1,114.77%
vs. Previous Quarter: 43.88%
ROE
06/30/25 - -
03/31/25 - -215.59
12/31/24 - -239.86
ROA
06/30/25 - -
03/31/25 - -27.23
12/31/24 - -30.32
Current Ratio
06/30/25 - -
03/31/25 - 3.74
12/31/24 - 1.62
Quick Ratio
06/30/25 - -
03/31/25 - 3.70
12/31/24 - 1.56
Operating Margin
06/30/25 - -
03/31/25 - -425.76
12/31/24 - -1,011.48
Net Margin
06/30/25 - -
03/31/25 - -1,516.06
12/31/24 - -3,239.02
Pre-Tax Margin
06/30/25 - -
03/31/25 - -1,514.57
12/31/24 - -3,225.04
Book Value
06/30/25 - -
03/31/25 - 0.36
12/31/24 - -0.70
Inventory Turnover
06/30/25 - -
03/31/25 - 6.62
12/31/24 - 7.11
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.20
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - 16.87
12/31/24 - -
 

Powered by Zacks Investment Research ©